Bibliography for MD7510 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies (DL) BETA

[1]

Amori, R.E. et al. 2007. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. JAMA. 298, 2 (Jul. 2007). DOI:https://doi.org/10.1001/jama.298.2.194.

[2]

Amy Kennedy 2013. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. PLoS ONE. 8, 3 (2013). DOI:https://doi.org/doi:  10.1371/journal.pone.0058861.

[3]

Anthony H. Barnett, Jenny Grice 2013. New Mechanisms in Glucose Control. BMJ Books; 1 edition.

[4]

[ARCHIVED CONTENT] Medicines management: Everybody’s business : Department of Health - Publications and statistics: http://webarchive.nationalarchives.gov.uk/20080205132320/http:/dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/dh_082200.

[5]

Atkinson, M.A. 2012. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine. 2, 11 (Nov. 2012), a007641–a007641. DOI:https://doi.org/10.1101/cshperspect.a007641.

[6]

Avery, L. et al. 2012. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. Diabetes Care. 35, 12 (Dec. 2012), 2681–2689. DOI:https://doi.org/10.2337/dc11-2452.

[7]

Bailey, C.J. et al. 2010. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. The Lancet. 375, 9733 (Jun. 2010), 2223–2233. DOI:https://doi.org/10.1016/S0140-6736(10)60407-2.

[8]

Bailey, Stephen Academic Writing : A Handbook for International Students.

[9]

Barry, V.W. et al. 2014. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. Progress in Cardiovascular Diseases. 56, 4 (Jan. 2014), 382–390. DOI:https://doi.org/10.1016/j.pcad.2013.09.002.

[10]

Bennett, W.L. et al. 2011. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. Annals of Internal Medicine. 154, 9 (May 2011). DOI:https://doi.org/10.7326/0003-4819-154-9-201105030-00336.

[11]

Bergenstal, R.M. et al. 2010. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine. 363, 4 (Jul. 2010), 311–320. DOI:https://doi.org/10.1056/NEJMoa1002853.

[12]

Bethel, M.A. et al. 2017. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care. 40, 4 (Apr. 2017), 494–501. DOI:https://doi.org/10.2337/dc16-1135.

[13]

Beverley M Shields 2015. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open. 5, 11 (2015). DOI:https://doi.org/doi:  10.1136/bmjopen-2015-009088.

[14]

Birkeland, K.I. 2015. Hyperglycaemia in pregnancy: still a lot to learn. The Lancet Diabetes & Endocrinology. 3, 10 (Oct. 2015), 752–753. DOI:https://doi.org/10.1016/S2213-8587(15)00282-X.

[15]

Brown, J. et al. 1996. Lifestyle interventions for the treatment of women with gestational diabetes. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

[16]

Buse, J.B. et al. 2010. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care. 33, 6 (Jun. 2010), 1255–1261. DOI:https://doi.org/10.2337/dc09-1914.

[17]

Buse, J.B. et al. 2009. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet. 374, 9683 (Jul. 2009), 39–47. DOI:https://doi.org/10.1016/S0140-6736(09)60659-0.

[18]

Buse, J.B. et al. 2011. Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine. 154, 2 (Jan. 2011). DOI:https://doi.org/10.7326/0003-4819-154-2-201101180-00300.

[19]

Capehorn, M. et al. 2017. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia                              ). Diabetic Medicine. (Mar. 2017). DOI:https://doi.org/10.1111/dme.13357.

[20]

Chimen, M. et al. 2012. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia. 55, 3 (Mar. 2012), 542–551. DOI:https://doi.org/10.1007/s00125-011-2403-2.

[21]

Choudhary, P. et al. 2012. Islet cell transplantation: current status in the UK (2012). Practical Diabetes. 29, 7 (Sep. 2012), 280–285. DOI:https://doi.org/10.1002/pdi.1707.

[22]

Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357.

[23]

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008: http://www.nice.org.uk/guidance/ta151.

[24]

Copeland, K.C. et al. 2013. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. PEDIATRICS. 131, 2 (Feb. 2013), 364–382. DOI:https://doi.org/10.1542/peds.2012-3494.

[25]

Courtney, H. et al. 2017. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Volume 10, (Mar. 2017), 79–87. DOI:https://doi.org/10.2147/DMSO.S126763.

[26]

Creme, P. and Lea, M.R. 2008. Writing At University: A Guide For Students. McGraw-Hill Education.

[27]

Dapagliflozin in combination therapy for treating type 2 diabetes June 2013: http://www.nice.org.uk/guidance/ta288.

[28]

Davies, M. et al. 2017. Introduction of biosimilar insulins in Europe. Diabetic Medicine. 34, 10 (Oct. 2017), 1340–1353. DOI:https://doi.org/10.1111/dme.13400.

[29]

Davies, M.J. et al. 2008. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 336, 7642 (Mar. 2008), 491–495. DOI:https://doi.org/10.1136/bmj.39474.922025.BE.

[30]

Dhatariya, K.K. et al. 2017. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. Diabetic Medicine. 34, 10 (Oct. 2017), 1361–1366. DOI:https://doi.org/10.1111/dme.13427.

[31]

Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period  (NG3: https://www.nice.org.uk/guidance/ng3.

[32]

Diamant, M. et al. 2010. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet. 375, 9733 (Jun. 2010), 2234–2243. DOI:https://doi.org/10.1016/S0140-6736(10)60406-0.

[33]

Dungan, K.M. et al. 2014. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet. 384, 9951 (Oct. 2014), 1349–1357. DOI:https://doi.org/10.1016/S0140-6736(14)60976-4.

[34]

Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015: https://www.nice.org.uk/guidance/ta248.

[35]

Fagin, J.A. and Wells, S.A. 2016. Biologic and Clinical Perspectives on Thyroid Cancer. New England Journal of Medicine. 375, 11 (Sep. 2016), 1054–1067. DOI:https://doi.org/10.1056/NEJMra1501993.

[36]

Ferrari, M. et al. 2017. Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. Diabetic Medicine. 34, 11 (Nov. 2017), 1546–1553. DOI:https://doi.org/10.1111/dme.13451.

[37]

Gale, E.A. 2013. Is type 2 diabetes a category error? The Lancet. 381, 9881 (Jun. 2013), 1956–1957. DOI:https://doi.org/10.1016/S0140-6736(12)62207-7.

[38]

Gallwitz, B. et al. 2012. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet. 380, 9840 (Aug. 2012), 475–483. DOI:https://doi.org/10.1016/S0140-6736(12)60691-6.

[39]

Grammes, J. et al. 2017. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. Diabetic Medicine. (Aug. 2017). DOI:https://doi.org/10.1111/dme.13506.

[40]

Gray, L.J. et al. 2014. External validation of two diabetes risk scores in a young UK South Asian population. Diabetes Research and Clinical Practice. 104, 3 (Jun. 2014), 451–458. DOI:https://doi.org/10.1016/j.diabres.2014.03.018.

[41]

Gray, L.J. et al. 2012. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia. 55, 12 (Dec. 2012), 3238–3244. DOI:https://doi.org/10.1007/s00125-012-2725-8.

[42]

Green, J.B. et al. 2015. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 373, 3 (Jul. 2015), 232–242. DOI:https://doi.org/10.1056/NEJMoa1501352.

[43]

Gregg, E.W. 2017. The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. Diabetes Care. (Aug. 2017). DOI:https://doi.org/10.2337/dci16-0055.

[44]

Guidelines: https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes.

[45]

Hadjiconstantinou, M. et al. 2016. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. Journal of Medical Internet Research. 18, 10 (Oct. 2016). DOI:https://doi.org/10.2196/jmir.5991.

[46]

Harman-Boehm, I. 2008. Continuous glucose monitoring in type 2 diabetes. Diabetes Research and Clinical Practice. 82, (Dec. 2008), S118–S121. DOI:https://doi.org/10.1016/j.diabres.2008.09.051.

[47]

Hartman, Y.A.W. et al. 2017. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. Diabetes Care. 40, 9 (Sep. 2017), e120–e121. DOI:https://doi.org/10.2337/dc17-0787.

[48]

Heinonen, I. et al. 2013. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. BMJ Open. 3, 6 (May 2013). DOI:https://doi.org/10.1136/bmjopen-2013-002901.

[49]

Henson, Joseph 2014. Associations of Sedentary Time with Fat Distribution in a High-Risk Population. (Nov. 2014).

[50]

Hessler, D.M. et al. 2017. Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. Diabetic Medicine. 34, 9 (Sep. 2017), 1228–1234. DOI:https://doi.org/10.1111/dme.13381.

[51]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[52]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[53]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[54]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[55]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[56]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[57]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[58]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[59]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[60]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[61]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[62]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[63]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[64]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[65]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[66]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[67]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[68]

Holt, R.I.G. et al. 2016. Textbook of Diabetes. John Wiley & Sons, Incorporated.

[69]

Holt, R.I.G. 2010. Textbook of diabetes. Wiley-Blackwell.

[70]

Inzucchi, S.E. et al. 2015. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 38, 1 (Jan. 2015), 140–149. DOI:https://doi.org/10.2337/dc14-2441.

[71]

Jelinek, H.F. et al. 2016. Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. Computers in Biology and Medicine. 75, (Aug. 2016), 90–97. DOI:https://doi.org/10.1016/j.compbiomed.2016.05.005.

[72]

John M Jakicic 2005. Physical activity considerations for the treatment and prevention of obesity. The American Journal of Clinical Nutrition. 82, 1 (Jan. 2005), 226S-229S.

[73]

Johnston, B.C. et al. 2014. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. JAMA. 312, 9 (Sep. 2014). DOI:https://doi.org/10.1001/jama.2014.10397.

[74]

Jones, A.G. and Hattersley, A.T. 2013. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine. 30, 7 (Jul. 2013), 803–817. DOI:https://doi.org/10.1111/dme.12159.

[75]

Kamlesh Khunti 2015. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE. 10, 9 (2015). DOI:https://doi.org/doi:  10.1371/journal.pone.0135702.

[76]

Kenneth Hodson 2010. Gestational diabetes: emerging concepts in pathophysiology. Obstetric Medicine. 3, 4 (2010). DOI:https://doi.org/doi:  10.1258/om.2010.100025.

[77]

Latika Sahu 2009. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. Obstetric Medicine. 2, 4 (2009). DOI:https://doi.org/doi:  10.1258/om.2009.080049.

[78]

Lee, I.-M. 2010. Physical Activity and Weight Gain Prevention. JAMA. 303, 12 (Mar. 2010). DOI:https://doi.org/10.1001/jama.2010.312.

[79]

Leelarathna, L. et al. 2017. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. Diabetic Medicine. 34, 10 (Oct. 2017), 1372–1379. DOI:https://doi.org/10.1111/dme.13412.

[80]

Leff, D.R. and Heath, D. 2009. Surgery for obesity in adulthood. BMJ. 339, sep22 1 (Sep. 2009), b3402–b3402. DOI:https://doi.org/10.1136/bmj.b3402.

[81]

Levin, P.A. et al. 2017. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Volume 10, (Apr. 2017), 123–139. DOI:https://doi.org/10.2147/DMSO.S130834.

[82]

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010: https://www.nice.org.uk/guidance/ta203.

[83]

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010: https://www.nice.org.uk/guidance/ta203.

[84]

Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing: https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/.

[85]

Marso, S.P. et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 375, 4 (Jul. 2016), 311–322. DOI:https://doi.org/10.1056/NEJMoa1603827.

[86]

Marso, S.P. et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 375, 4 (Jul. 2016), 311–322. DOI:https://doi.org/10.1056/NEJMoa1603827.

[87]

Marso, S.P. et al. 2016. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. (Sep. 2016). DOI:https://doi.org/10.1056/NEJMoa1607141.

[88]

Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence.  CG76, Jan 2009: https://www.nice.org.uk/guidance/cg76.

[89]

Merlin C. Thomas 2016. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Therapy. 7, 3 (2016). DOI:https://doi.org/doi:  10.1007/s13300-016-0189-4.

[90]

Min, S.H. et al. 2017. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes/Metabolism Research and Reviews. 33, 1 (Jan. 2017). DOI:https://doi.org/10.1002/dmrr.2818.

[91]

Mishriky, B.M. et al. 2015. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice. 109, 2 (Aug. 2015), 378–388. DOI:https://doi.org/10.1016/j.diabres.2015.05.025.

[92]

Moreno-Castilla, C. et al. 2016. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. Current Diabetes Reports. 16, 4 (Apr. 2016). DOI:https://doi.org/10.1007/s11892-016-0717-7.

[93]

Narendran, P. et al. 2017. Exercise to preserve β-cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. Diabetic Medicine. 34, 11 (Nov. 2017), 1521–1531. DOI:https://doi.org/10.1111/dme.13439.

[94]

National Obesity Observatory: http://www.noo.org.uk.

[95]

Nauck, M. et al. 2014. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care. 37, 8 (Aug. 2014), 2149–2158. DOI:https://doi.org/10.2337/dc13-2761.

[96]

Nauck, M.A. et al. 2007. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism. 9, 2 (Mar. 2007), 194–205. DOI:https://doi.org/10.1111/j.1463-1326.2006.00704.x.

[97]

Nauck, M.A. and Meier, J.J. 2016. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The Lancet Diabetes & Endocrinology. 4, 6 (Jun. 2016), 525–536. DOI:https://doi.org/10.1016/S2213-8587(15)00482-9.

[98]

Nissen, S.E. and Wolski, K. 2007. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. New England Journal of Medicine. 356, 24 (Jun. 2007), 2457–2471. DOI:https://doi.org/10.1056/NEJMoa072761.

[99]

Noctor, E. and Dunne, F. 2015. Postnatal testing following gestational diabetes. The Lancet Diabetes & Endocrinology. 3, 10 (Oct. 2015), 761–762. DOI:https://doi.org/10.1016/S2213-8587(15)00322-8.

[100]

Nolan, C.J. et al. 2015. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes. 64, 3 (Mar. 2015), 673–686. DOI:https://doi.org/10.2337/db14-0694.

[101]

Paul Craddy 2014. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Therapy. 5, 1 (2014). DOI:https://doi.org/doi:  10.1007/s13300-014-0061-3.

[102]

Perrin, N.E. et al. 2017. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. Diabetic Medicine. 34, 11 (Nov. 2017), 1508–1520. DOI:https://doi.org/10.1111/dme.13448.

[103]

Persaud, S.J. and Jones, P.M. 2016. A Wake-up Call for Type 2 Diabetes? New England Journal of Medicine. 375, 11 (Sep. 2016), 1090–1092. DOI:https://doi.org/10.1056/NEJMcibr1607950.

[104]

Pickup, J.C. 2012. Insulin-Pump Therapy for Type 1 Diabetes Mellitus. New England Journal of Medicine. 366, 17 (Apr. 2012), 1616–1624. DOI:https://doi.org/10.1056/NEJMct1113948.

[105]

Qin, L. et al. 2010. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. European Journal of Epidemiology. 25, 1 (Jan. 2010), 5–12. DOI:https://doi.org/10.1007/s10654-009-9395-y.

[106]

Rasouli, B. et al. 2017. Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. Diabetic Medicine. 34, 9 (Sep. 2017), 1259–1263. DOI:https://doi.org/10.1111/dme.13410.

[107]

Riddle, M.C. et al. 2013. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 36, 9 (Sep. 2013), 2489–2496. DOI:https://doi.org/10.2337/dc12-2454.

[108]

Rinki Murphy 2015. Monogenic diabetes and pregnancy. Obstetric Medicine. 8, 3 (2015). DOI:https://doi.org/doi:  10.1177/1753495X15590713.

[109]

Rizos, C.V. et al. 2016. The current role of thiazolidinediones in diabetes management. Archives of Toxicology. 90, 8 (Aug. 2016), 1861–1881. DOI:https://doi.org/10.1007/s00204-016-1737-4.

[110]

Rotz, M.E. et al. 2015. Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice. 69, 5 (May 2015), 531–549. DOI:https://doi.org/10.1111/ijcp.12572.

[111]

Ryder, B. et al. 2013. ABCD position statement on GLP-1 based therapies and pancreatic damage. Practical Diabetes. 30, 9 (Nov. 2013), 388–391. DOI:https://doi.org/10.1002/pdi.1816.

[112]

S M Attard 2015. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes. 5, 6 (2015). DOI:https://doi.org/doi:  10.1038/nutd.2015.16.

[113]

Sallis, J.F. et al. 2016. Progress in physical activity over the Olympic quadrennium. The Lancet. 388, 10051 (Sep. 2016), 1325–1336. DOI:https://doi.org/10.1016/S0140-6736(16)30581-5.

[114]

Samuel, V.T. and Shulman, G.I. 2012. Intergrating Mechanisms  for Insulin Resistance: Common Threads and Missing Links. Cell. 148, 5 (Mar. 2012), 852–871. DOI:https://doi.org/10.1016/j.cell.2012.02.017.

[115]

Schauer, P.R. et al. 2017. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine. 376, 7 (Feb. 2017), 641–651. DOI:https://doi.org/10.1056/NEJMoa1600869.

[116]

Schauer, P.R. et al. 2017. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. New England Journal of Medicine. 376, 7 (Feb. 2017), 641–651. DOI:https://doi.org/10.1056/NEJMoa1600869.

[117]

Schauer, P.R. et al. 2012. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. New England Journal of Medicine. 366, 17 (Apr. 2012), 1567–1576. DOI:https://doi.org/10.1056/NEJMoa1200225.

[118]

Schwartz, S.S. et al. 2016. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care. 39, 2 (Feb. 2016), 179–186. DOI:https://doi.org/10.2337/dc15-1585.

[119]

Sivasubramaniyam, S. et al. 2017. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. Diabetic Medicine. 34, 10 (Oct. 2017), 1456–1460. DOI:https://doi.org/10.1111/dme.13438.

[120]

Sjöström, L. et al. 2004. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. New England Journal of Medicine. 351, 26 (Dec. 2004), 2683–2693. DOI:https://doi.org/10.1056/NEJMoa035622.

[121]

Srinivasan, P. et al. 2007. Islet cell transplantation. Postgraduate Medical Journal. 83, 978 (Apr. 2007), 224–229. DOI:https://doi.org/10.1136/pgmj.2006.053447.

[122]

Steven, S. et al. 2016. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care. 39, 5 (May 2016), 808–815. DOI:https://doi.org/10.2337/dc15-1942.

[123]

Steven, S. and Taylor, R. 2015. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. Diabetic Medicine. 32, 9 (Sep. 2015), 1149–1155. DOI:https://doi.org/10.1111/dme.12722.

[124]

Stewart, Z.A. et al. 2016. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. New England Journal of Medicine. 375, 7 (Aug. 2016), 644–654. DOI:https://doi.org/10.1056/NEJMoa1602494.

[125]

Tanner, M. 2016. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. Annals of Internal Medicine. 165, 4 (Aug. 2016). DOI:https://doi.org/10.7326/ACPJC-2016-165-4-020.

[126]

Tao, L. et al. 2015. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabetic Medicine. 32, 7 (Jul. 2015), 907–919. DOI:https://doi.org/10.1111/dme.12711.

[127]

Umpierre, D. 2011. Physical Activity Advice Only or Structured Exercise Training and Association With HbA                              Levels in Type 2 Diabetes. JAMA. 305, 17 (May 2011). DOI:https://doi.org/10.1001/jama.2011.576.

[128]

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care: http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview.

[129]

Villani, M. et al. 2017. Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine. 34, 9 (Sep. 2017), 1205–1211. DOI:https://doi.org/10.1111/dme.13379.

[130]

Vloemans, A.F. et al. 2017. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. Diabetic Medicine. 34, 10 (Oct. 2017), 1470–1476. DOI:https://doi.org/10.1111/dme.13429.

[131]

Wanner, C. et al. 2016. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 375, 4 (Jul. 2016), 323–334. DOI:https://doi.org/10.1056/NEJMoa1515920.

[132]

William H. Polonsky,Lawrence Fisher,Jay Earles,R. James Dudl,Joel Lees,Joseph Mullan Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. Diabetes Care.

[133]

Yates, T. and Davies, M.J. 2017. Physical activity and Type 1 diabetes: an underused therapy. Diabetic Medicine. 34, 11 (Nov. 2017), 1498–1499. DOI:https://doi.org/10.1111/dme.13445.

[134]

Yeh, J.S. et al. 2016. Obesity and Management of Weight Loss. New England Journal of Medicine. 375, 12 (Sep. 2016), 1187–1189. DOI:https://doi.org/10.1056/NEJMclde1515935.

[135]

Young-Hyman, D. et al. 2017. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140. Diabetes Care. 40, 2 (Feb. 2017), 287.1-287. DOI:https://doi.org/10.2337/dc17-er02.

[136]

Zaccardi, F. et al. 2016. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgraduate Medical Journal. 92, 1084 (Feb. 2016), 63–69. DOI:https://doi.org/10.1136/postgradmedj-2015-133281.

[137]

A Randomised trial of the effect and cost-effectiveness of early intensive mulitfactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diaberes:the anglod-Danish-Dutch Study of intensive Treatment in People with Screen-Detected Diabetes in Primary care (ADDITION-Europe) study.

[138]

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE.

[139]

Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE.

[140]

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists  in type 2 diabetes  Systematic review and mixed-treatment comparison analysis.

[141]

2016. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 375, 18 (Nov. 2016), 1799–1802. DOI:https://doi.org/10.1056/NEJMc1611290.

[142]

Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. Journal of diabetes science and technology (Online). 3, 4.

[143]

2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 375, 18 (Nov. 2016), 1797–1799. DOI:https://doi.org/10.1056/NEJMc1611289.

[144]

2015. Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care. 38, 8 (Aug. 2015), 1583–1591. DOI:https://doi.org/10.2337/dc15-0279.

[145]

NHS Evidence: an introduction.

[146]

Obesity: identification, assessment and management | Guidance and guidelines | NICE.

[147]

2015. Standards of Medical Care in Diabetes--2015: Summary of Revisions. Diabetes Care. 38, Supplement_1 (Jan. 2015), S4–S4. DOI:https://doi.org/10.2337/dc15-S003.

[148]

2016. The Eatwell Guide. Public Health England.

[149]

Type 2 diabetes in adults: management | Guidance and guidelines | NICE.

[150]

Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE.

[151]

Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE.